Quinuclidine derivatives as muscarinic M3 receptor antagonists
US8329729B2 · kind B2 · utility
1Cited by
3References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 13, 2008 |
| Grant date | Dec 11, 2012 |
| Priority date | — |
| Expiry date | May 23, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides named compounds of formula (I), wherein R4 is a N-substituted quinuclidine (I) pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions. Their use in therapy for the treatment of conditions mediated by M3 muscarinic receptors, such as chronic obstructive pulmonary disease is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.